Replies to post #208 on BioVie Inc (BIVI)

[loanranger]

"Following the Merger, the Registrant will continue the development of LAT’s lead clinical therapeutic candidate Continuous low-dose Infusion (CI) Terlipressin."

http://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-for-novel-terlipressin-formulation-for-the-treatment-of-ascites-185655002.html

http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=374812
(enter "Terlipressin" and see PGC-C12E-terlipressin)

http://pharmain.bilberrysoft.com/pipeline/

The dumping of the LAT website put a crimp in my work, but here's a cached page from it:
http://webcache.googleusercontent.com/search?q=cache:f2HjDuXi9OoJ:www.lat-pharma.com/+&cd=1&hl=en&ct=clnk&gl=us

Was bored. This helped.

GL.



ps. It's tough to tell exactly who coughed these up:
"certain shareholders of the Company collectively agreed to retire and cancel an aggregate of 39,820,000 shares of Common Stock"
See p.47 of http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10936094#NNAB-20150630_10K_HTM_A_016


pps. You probably know this, but the NNAB trading has been almost non-existent:
http://ih.advfn.com/stock-market/USOTC/nanoantibiotics-inc-NNAB/historical